

Organised by



Supported by



# Recent Trends of Androgen Depletion Therapy on Prostate Cancer in Asia

**21<sup>st</sup> July 2021, Wednesday**

**7.00PM - 8.00PM**  
SG Time

Androgen deprivation therapy (ADT), alone or in combination, remains the mainstay of first-line treatment for locally advanced and early-stage metastatic prostate cancer. Emerging data seems to present different clinical profile of different modalities of ADT including Gonadotropin-releasing hormone (GnRH) antagonist and agonist. This webinar brings together medical experts from Asia to share and discuss current evidence of GnRH antagonist in prostate cancer management, in clinical studies and real-world setting for Asian patients.

## Speakers



**Prof Ng Chi Fai, Anthony**  
The Chinese University of Hong Kong



**Prof Hiroji Uemura**  
Yokohama City University Medical Center

## PROGRAMME

- 7.00pm Opening and speaker introduction**  
Prof. NG Chi Fai, Anthony
- 7.05pm The role of LHRH antagonists in the treatment of prostate cancer: perspective from Japanese experiences**  
Prof. Hiroji Uemura
- 7.35pm Reflection on clinical considerations for PCa management in Asia**  
Prof. NG Chi Fai, Anthony
- 7.50pm Panel discussion**  
All
- 8.00pm Closing remarks**  
Prof. NG Chi Fai, Anthony

CME accreditation pending

**Complimentary registration**

[https://zoom.us/webinar/register/WN\\_V3Eey4C6TXaE66CqHyg8fw](https://zoom.us/webinar/register/WN_V3Eey4C6TXaE66CqHyg8fw)

